Vyome Holdings (HIND) FCF Margin (2015 - 2026)
Vyome Holdings (HIND) posted FCF Margin of 3352.67% for Q2 2026, up 26.24% on a QoQ basis from 4545.48% in Q1 2026, and down 273960.0% year-over-year from N/an in Q2 2025.
Powered by 
Analysis
Vyome Holdings (HIND) FCF Margin (2015 - 2026) Analysis & Trends
Vyome Holdings has reported FCF Margin for 12 years, with the latest figure at 3352.67% in Q2 2026.
- On a quarterly basis, FCF Margin fell 273960.0% year-over-year to 3352.67% in Q2 2026; TTM through Jun 2026 was 4300.47%, a 488479.0% decrease from a year earlier, with the FY2025 full-year figure at 1172.56%, down 93355.0% from the prior year.
- FCF Margin was 3352.67% for Q2 2026 at Vyome Holdings, up from 4545.48% in the prior quarter.
- The five-year high for FCF Margin was 3333.69% in Q3 2024, with the low at 5085.25% in Q3 2025.
- Average FCF Margin over 5 years is 898.62%, with a median of 206.19% recorded in 2023.
- The sharpest annual moves came in 2024 and 2025: FCF Margin jumped 346269 bps in 2024, then tumbled 841894 bps in 2025.
- Over 5 years, FCF Margin stood at 92.64% in 2022, then plunged by 34 bps to 123.97% in 2023, then soared by 96 bps to 4.83% in 2024, then plunged by 83602 bps to 4044.21% in 2025, then advanced by 17 bps to 3352.67% in 2026.
- The last three FCF Margin figures came in at 3352.67% (Q2 2026), 4545.48% (Q1 2026), and 4044.21% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | -3,352.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,352.67% |
| Mar 31, 2026 | -4,545.48% |
| Dec 31, 2025 | -4,044.21% |
| Sep 30, 2025 | -5,085.25% |
| Jun 30, 2025 | -613.07% |
| Mar 31, 2025 | -102.49% |
| Dec 31, 2024 | -4.83% |
| Sep 30, 2024 | 3,333.69% |
| Jun 30, 2024 | -69.06% |
| Mar 31, 2024 | -106.58% |
| Dec 31, 2023 | -123.97% |
| Sep 30, 2023 | -129.00% |
| Jun 30, 2023 | -296.98% |
| Mar 31, 2023 | -221.78% |
| Dec 31, 2022 | -92.64% |
| Sep 30, 2022 | -190.60% |
| Jun 30, 2022 | -227.52% |
| Mar 31, 2022 | -302.75% |
| Sep 30, 2021 | -207.87% |
| Jun 30, 2021 | -49.05% |